AFP, a glycoprotein widely utilized in diagnosing and monitoring liver cancer, exhibits a sensitivity of only 60% at the optimal threshold (10–20 ng/mL) for HCC, with limited specificity (Jing et al., 2020; Trevisani et al., 2001). Here, AFP is linked to hepatocellular carcinoma.